Germany is one of the few countries that has embraced medical cannabis. The country’s cannabis market is worth $1 billion and growing, but it faces challenges from other European countries such as France and Italy who are looking to take a bite out of the pie.
The cbd in germany is a marketing campaign that has been started by the German Medical Association. The campaign aims to educate people about cannabis and its medical benefits.
The German procedure is unlike anything outsiders have ever encountered, with unexpected twists and turns at every turn that often defy logic.
The medicinal cannabis industry in Germany is one of the world’s biggest. Indeed, as of 2021, it is not only Europe’s biggest market, but also the driving force for production plans in several sunny and lower-cost locations. This is true of nations in the European Union (EU) as well as countries farther afield, all seeking to export cannabis to a country that, by design, has not been allowed to obtain medicinal cannabis locally.
That’s all well and dandy, but here’s the good news.
In reality, the pharmaceutical infrastructure that medical cannabis businesses must contend with is neither transparent nor simple to traverse. This is why.
Cannabis is classified as a controlled narcotic drug under federal law.
The first problem that all distributors in the German market face is that cannabis is classified as a narcotic by the German government. Despite a European ruling last autumn, this includes low THC hemp, which has resulted in a number of litigation and humiliating spats recently, even on a non-medical, commercial level.
Beyond that, however, cannabis as a medication is obviously present in the system—but just importing and/or registering strains and brands (regardless of who produces them or where the flower or products originate from) is insufficient to generate sales.
Pharmaceutical medicines, unlike in the United States, may not be marketed directly to prospective customers (also known as patients).
As a consequence, cannabis specialist distributors, like regular pharmaceutical distributors, are forced to go through a bizarre, inefficient, and costly three-step procedure to acquire prescriptions, which begins but does not finish with what is euphemistically referred to as “doctor education.”
Step after grueling step
For all fledgling distributors who have never done business before and want to leap right into the cannabis speciality industry, the initial pre-step is still very tough. Specifically, they must find a suitable supplier before they can acquire final licenses and permissions. Because there is only one distributor that handles domestically produced cannabis in the nation, everyone else must locate businesses willing to deal with them.
This might have meant one of two things five years ago. Look for a Canadian business that wants to expand into Europe and Germany, or go to Bedrocan, a Dutch grower just over the border. Bedrocan started to restrict both the quantity of cannabis it was willing to sell per distributor and the number of distributors it was willing to deal with as a consequence of the early rush.
German Cannabis Prescriptions: Difficulties and Dichotomies
The true battle starts after a distributor has at least one offtake agreement with a recognized business in place, as well as the necessary licenses and permissions. Beyond acquiring the necessary permits and procuring the product, distributors must do many (expensive and time-consuming) things to have their strain or brand of cannabis offered in German pharmacies. When they do get in front of a cannabis prescribing doctor, they must educate physicians about their strain or product and find patients to advocate for their brand.
Finding a doctor for the privately insured is no longer a problem, especially in bigger cities. Doctors who work at “Schmerz zentren” (pain clinics) are generally sympathetic to patients who have a proven, pre-diagnosed ailment. It is also not required to get a recommendation from a general practitioner if one has private insurance. The patient must, however, pay for both the doctor’s appointment and the cannabis up front and out of pocket.
The struggle is considerably harder for individuals with statutory or “public” health insurance, which begins with locating willing physicians. However, after the patient has been located, the doctor must work with them to fill out paperwork and wait for clearance from the regional approvers (not even individual health insurers). Patients may then request the cannabis brand of their choice after their application has been approved. Assuming the doctor is sympathetic and does so, they must then take this prescription to a specialized pharmacy, which will have the exact brand printed on the paper itself. These pharmacies may now place overnight orders.
Whatever the case may be, none of this is simple. To far, distributors have attempted to contact both the general public and prescribing physicians through a number of tactics (including free publicity, employing pharma reps, and sponsoring events). To make matters even more complicated, physicians’ availability and willingness to prescribe differs by state.
The Frankfurt municipal organization in charge of educating new cannabis physicians, for example, would not reveal the identities of the doctors it has educated. Furthermore, according to High Times, most physicians in the state of Hesse who deal with statutory health insurance patients refuse to take on more than two cannabis patients per practice.
Generic Extracts in the Future
Given all of these issues, as well as the considerable markup, liquid dronabinol, the worldwide generic, 96 percent THC extract, is now quite popular in the German market. What is the cause behind this? Because of the “generic” status, it is simpler to advertise to both physicians and patients, as well as get clearance from health insurance.
Most people, however, do not wish to take this extract and prefer to use alternative medicines or therapies instead.
Patient Outreach Is Still Important, but It’s Difficult
In Germany, every distributor runs an online patient outreach program. Indeed, patient groups on Facebook and other social media platforms are quite common. This, however, is far from a cure-all. Patients are as committed to particular brands as they are to finding a consistent supply and source for their medication.
Unfortunately, in a nation where cannabis is covered by insurance at least by law, but where the first patient did not get a guaranteed yearlong prescription until late last year, this remains by far the most difficult barrier to overcome.
Marketing any kind of cannabis, via any source, conventional or not, is an uphill battle until any of these factors change—through legal challenges or more legislative changes.
The cbd stocks to watch is a company that has been in the German market for medical cannabis. The company is relatively new, but has already made some big moves.
- prohibition partners germany,
- dronabinol germany